HIV protease (PR) is a proven target for drugs that suppress HIV AIDS, but treatment leads to multi-drug-resistant mutants. As a strategy to defeat the evolution of viral resistance, we are employing fragment based lead discovery to develop novel classes of allosteric PR inhibitors able to act in synergy with FDA approved drugs.